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Factors That Promote the Development
of Human Breast Cancer
by David B. Thomas*
Epidemiologic and endocrinologic studies of breast cancer etiology are reviewed in the context of
the Moolgavkar two-stage model for mammary carcinogenesis. Promoters are hypothesized to en-
hance the growth of stem and intermediate cells, and initiators are assumed to cause stem and
intermediate cells to give rise to intermediate and tumor cells, respectively. Although all
epidemiologic features of breast cancer can be explained in terms of the cellular events supposed by
the model, the specific causes of breast cancer are largely unknown. Aberrations in endogenous
steroid sex hormones most probably act as promoters, although their exact nature and etiology are
unclear. Ionizing radiation is the only known initiator. The two-stage model implies that others
exist and that they are responsible for both the international variation in risk of breast cancer, and
its familial aggregation. Results of endocrinologic studies suggest either that aberrations in en-
dogenous sex hormones serve as such initiators or are correlated with them, or that familial and
international variations in risk are mediated by promoters.
Introduction
Many epidemiologic studies, conducted largely
during the past three decades, have resulted in the
identification of a number of factors that distinguish
women who are at increased risk of breast cancer.
A number of investigators have attempted to syn-
thesize information from epidemiologic studies,
along with findings from clinical and laboratory in-
vestigations, and develop models or hypothesis for
the etiology of breast cancer. In spite of these ef-
forts, the specific causes of breast cancer are largely
unknown.
The purposes of this paper are to critically sum-
marize the epidemiologic features of breast cancer,
describe the more promising etiologic hypotheses
and models that have been proposed, and indicate
additional studies that might enhance our under-
standing of the genesis of this disease.
Risk Factors for Breast Cancer
A critical review of the epidemiology of breast
cancer was published in 1980 (1) and should be con-
sulted for documentation of the risk factors summa-
rized in Tables 1 and 2. Table 1 shows factors that
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strongly implicate ovarian hormones as etiologic
agents. Risk of breast cancer is approximately 100
times greater in women than men. In women, the
disease does not occur before menarche. Thereafter
the incidence increases rapidly with age until meno-
pause, after which time it increases more slowly
with advancing years. Risk of breast cancer is
inversely related to age at menarche. This adverse
effect of earlier onset of ovarian function appears to
diminish with age. Risk also increases with age at
menopause, and premenopausal oophorectomy,
without exogenous estrogen replacement therapy,
reduces the risk of breast cancer, the degree of pro-
tection being inversely related to the age at which
the ovaries are removed. The adverse consequences
of prolonged ovarian function and the protective ef-
fect of premenopausal oophorectomy appear to in-
crease with age.
Nulliparous women are at greater risk of breast
cancer than parous women, and the risk in women
who have had children increases with the age at
which their first child is born. Results of some
studies show that having additional children may
also be weakly protective. The reduction in risk as-
sociated with an early first birth may diminish as a
woman ages. Lactation does not appear to alter the
risk of breast cancer, although in one study women
with breast cancer who breast fed from only one
breast tended to develop their tumors in the breast
that was not used for nursing (2).Table 1. Risk factors for breast cancer: factors implicating hormones as tumor promoters.
Factor Influence on risk Remarks
Female sex Increases risk
Age Increases risk Effect ofage diminishes after menopause
Age at menarche Inversely related to risk Influence diminishes with age
Age at menopause Directly related to risk Influence increases with age
Oophorectomy Protection inversely related to Influence increases with age
age at oophorectomy
Nulliparity Increases risk
Age at first child Directly related to risk Influence diminishes with age
(early birth protective)
Parity Additional children may be weakly protective
Lactation Minimal Unilateral nursing may influence laterality of
tumor
Exogenous estrogens Probably eliminates the protective Results ofstudies conducted
effect ofoophorectomy. Risk in to date are inconsistent
women with intact ovaries uncertain
Table 2. Risk factors for breast cancer: probable tumor initiators and factors with unknown mechanisms of action.
Factor Influence on risk Remarks
Ionizing radiation Increases risk Dose-response, probably linear
Family history of breast cancer Increases risk May be multiple explanations
Geography High risk in "western" countries Not explainable by known risk factors
Nutritional factors "Western diet," fats, may increase risk Effect may be indirect
Weight May increase risk Effects mainly postmenopausal disease; not
confounded by age at menarche
Height Questionable increase in risk Results ofstudies inconsistent
Body size Questionable increase in risk Results ofstudies inconsistent
Benign breast disease Increases risk Lesions with epithelial proliferation and
calcification particularly increase risk.
Transvestite males given high doses of estrogens
to induce breast development have developed
breast cancer, but studies of more moderate doses
of estrogens given to women for treatment of meno-
pausal symptoms (3-7), or with progestogens in the
form of oral contraceptives (3, 9-11), have yielded in-
consistent results. Estrogen therapy probably
eliminates the protective effect of premenopausal
oophorectomy (6, 7, 12), but results of some studies
are not supportive ofthis statement (4, 5).
Table 2 summarizes other factors that have been
related to breast cancer. Ionizing radiation is the
only known cause of this disease. Although such
radiation is undoubtedly responsible for only a
minute proportion of all breast cancer, as discussed
subsequently, its influence on risk of breast cancer
is age-dependent, and this observation has provided
insight into possible mechanisms of tumor initiation
and promotion.
Risk is approximately doubled in mothers, sis-
ters, and daughters ofwomen with breast cancer, as
well as in both their maternal and paternal grand-
mothers and aunts (1). Such familial aggregation
could result from either common environmental or
genetic factors, and different mechanisms are prob-
ably operative in various situations. The compar-
able risks in maternal and paternal relatives rule
out x-linked genetic mechanisms, or transmission of
an oncogenic agent via the placenta or breast milk,
and the latter is also refuted as a vehicle by the ob-
servation that women who were breast fed are not
at increased risk.
Evidence for genetic mechanisms are as follows:
(a) familially aggregated breast cancers tend to oc-
cur in premenopausal women and to be bilateral
more frequently than nonfamilial tumors (13-15); (b)
the risk in sisters and daughters of propositi with
breast cancer is enhanced if the propositus has a
second-degree relative with breast cancer, is in-
creased even more if she has an affected sister, and
is greatest if her mother also had breast cancer (13,
14); (c) risk of breast cancer is no greater in
dizygotic twins of cases than in other sisters (about
doubled), but is increased sixfold in monozygotic
twins (16); and (d) the lesions occurred on the same
side in eight of nine twins that were concordant for
breast cancer (16).
In spite of these observations, no simple Mendel-
ian mode of inheritance of breast cancer is evident.
One exception to this is an observation made in 11
high-risk families in which the pattern of occurrence
of breast cancer was compatible with an autosomal
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dominant gene chromosomally linked to the gluta-
mate-pyruvate transaminase locus (17). This linkage
was not found in other high-risk families and prob-
ably accounts for only a tiny portion of all breast
cancer. It has, nonetheless, provided an important
new etiologic lead.
Incidence rates of breast cancer vary among
countries by a factor of nearly eight. Rates are high-
est in Caucasian populations of North America and
lowest in parts of Africa, Japan, and among non-
Jews in Israel. Migrants from low- to high-risk coun-
tries have intermediate rates of breast cancer, and
rates gradually approach those of the high-risk
country in succeeding generations. In the United
States, this "movement" of rates is more rapid in
migrants and their decendents from Western
Europe than in more culturally distinct groups such
as Japanese, Chinese and Mexicans (1). These obser-
vations clearly show the international differences in
rates to be of environmental rather than genetic ori-
gin and due to factors associated with a "western"
life style. The international differences have been
shown not to be due to variations in the prevalence
of any of the risk factors that have so far been men-
tioned. Large increases in rates of breast cancer in
succeeding generations of women in Iceland (18) and
Japan (19) have similarly been associated with
changes from traditional to modern societies and
not to temporal changes in the known risk factors
for breast cancer.
Rates of breast cancer have been shown to be
correlated with total fat consumption among vari-
ous countries (20-22), temporally and among dis-
tricts in Japan (19) and among five ethnic groups in
Hawaii (23).
Similar correlations have been observed, al-
though somewhat less consistently, with meat con-
sumption (19, 21-23). Case-control studies in Canada
(24) and among Seventh Day Adventists in the
United States (25) have also related risk of breast
cancer to total fat consumption, and preliminary re-
sults from a prospective study in Japan (19) show
risk to be related to meat consumption. The spouses
of Japanese women with breast cancer in Hawaii
(and presumably also the cases themselves) were
found to have previously consumed more meat and
dairy products and less traditional Japanese food
than spouses of normal women (26). Finally, a high
fat diet has been shown to increase mammary
tumor production both in rats exposed and not
exposed to the mammary carcinogen, 7,12- dimeth-
ylbenz(a)anthracene (DMBA) (27). Although each ob-
servation relating fat and meat consumption to risk
of breast cancer can be faulted, in the aggregate
they strongly suggest that diets rich in fats and
meats, or unknown factors strongly correlated with
such diets, increase one's risk of breast cancer.
Studies of the relationship of breast cancer to
height, weight, and body size have recently been re-
viewed (1). Findings among studies are inconsistent
and difficult to interpret. The most consistent
finding (but with several exceptions) is an associa-
tion of postmenopausal breast cancer with weight.
Adult weight is obviously related to nutritional
factors and has been inversely correlated with age
at menarche and directly related to age at
menopause (28). The association of weight with
breast cancer may thus be indirect.
The risk of breast cancer is roughly doubled in
women with previous benign breast lesions. The in-
crease is largely confined to women with fibrocystic
lesions characterized by proliferation of ductal epi-
thelial cells (29, 30). Risk may be particularly high if
there is histologic evidence of calcification of these
lesions (29 and D. L. Page, personal communication).
The Moolgavkar Model
Moolgavkar et al. (31) have proposed a two- stage
model for the genesis of breast cancer. They hypo-
thesize that malignancies develop from undifferenti-
ated stem cells as a result of two independent
events that occur during cell division. A normal
stem cell can either die or differentiate, and thus
not be at further risk of potentially malignant
change, divide into two normal stem cells (each of
which are at risk), or divide into one normal cell and
one intermediate cell. Intermediate cells can
similarly die or differentiate and thus be removed
from the pool of cells at risk of a second event,
divide into two intermediate cells, or divide into one
intermediate and one transformed cell. The trans-
formed cell then grows into a tumor. The exact
nature of the hypothesized event is unknown, but
may be viewed as a failure of normal cell division in
which one of the two daughter cells is not an exact
replica of the parent cell. An event may also be
viewed as the cumulative effect on a cell of tumor
initiators. Tumor promotors, on the other hand,
would act by enhancing normal proliferation of stem
or intermediate cells.
An elegant mathematical model was developed
which included terms representing the net growth
rates of stem and intermediate cells and terms for
the probabilities of stem and intermediate cells giv-
ing rise to intermediate and tumor cells, respec-
tively. By assigning different values to the net cell
growth terms, before and after menopause, and dif-
ferent values for the probabilities of events in
different human populations, the model accurately
simulated the age-incidence curve for breast cancer
in six populations with markedly different overall
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incidence rates. In biological terms; the interna-
tional differences in rates would be due to different
risks of exposure to tumor initiators; the rapid
increase in risk with age between menarche and
menopause in all areas would be due to the pro-
liferation of stem and intermediate cells, largely
between the ages of 12 and 18; and the decline in
the slope of the incidence curves with age after
menopause would be due to the decrease in rates of
division (or more differentiation or death) of stem or
(especially) intermediate cells associated with cessa-
tion of ovarian function.
Pregnancy initially causes proliferation, but then
marked differentiation of the mammary epithelial
cells. The latter would reduce the number of cells at
risk of events; and the earlier in life that this hap-
pened, the shorter would be the time when large
numbers of undifferentiated susceptible cells are
present in the breast, and the lower would be the
risk of breast cancer. The model accurately simu-
lated the inverse relationship between age at birth
of first child and risk of breast cancer.
The other risk factors shown in Table 1 can like-
wise be explained in terms of the Moolgavkar model
as being indicators of hormonal events that promote
(or retard) the growth of stem and intermediate
cells. Females have more such cells than males and
are thus at much greater risk. Early age at men-
arche as a risk factor is explainable by the fact that
large numbers of stem cells are present for a longer
period of time in women with an early than late
menarche. If the model is correct, risk should be re-
lated to the length of time from menarche to birth
of first child; and this was observed in a study com-
pleted since the model was developed (32). Young
age at natural menopause or oophorectomy as pro-
tective factors are explained by the fact that cessa-
tion of ovarian function causes involution of the
breast and removal of stem and intermediate cells.
To the extent that exogenous estrogens retard this
process they would be expected to eliminate the
protective effect of a premenopausal oophorectomy
or early natural menopause. The possible small pro-
tective effect of pregnancies subsequent to the first
could be due to slight additional differentiation of
the mammary epithelium.
The first three factors in Table 2 most likely rep-
resent initiators. Ionizing radiation certainly can
cause genetic mutations which could result in
events in terms of the model. Knudson (33, 34) has
proposed that if the first event in a two-hit model is
in a germ cell, then all mammary cells would be in-
termediate cells and require only one additional
event for tumor development. This would explain
the younger age at onset of familial cancers and
their tendency to be bilateral. The geographic dif-
ferences in rates of breast cancer were successfully
simulated by the model by assuming that they were
due to enhancement of the rates oftransition, which
implies that they are due to differences in levels of
initiators in different countries. Weight, height, and
body size presumably reflect nutritional status,
which is discussed subsequently.
The role of benign breast lesions can be explained
in terms of the model by assuming that lesions char-
acterized by epithelial proliferation represent inter-
mediate cells. Noninvasive carcinomas (lobular carci-
noma in situ and intraductal carcinoma) may similar-
ly be indicative of intermediate cells (31).
In summary, the Moolgavkar model nicely relates
the epidemiologic features of breast cancer to prob-
able events occurring at the cellular level. Hormo-
nal risk factors are hypothesized to represent pro-
motors which enhance the growth of stem and inter-
mediate cells, and nonhormonal factors are seen
likely to represent causes of mutations in individual
cells that result in transformations of normal stem
cells to intermediate cells and of intermediate cells
to fully initiated tumor cells. Intermediate cells are
seen to have the ability to proliferate and cause be-
nign or noninvasive tumors but not to invade nor-
mal tissues, whereas a fully transformed cell will
grow and invade and thus develop into a malig-
nancy.
Although the model provides a logical description
of what may happen at the cellular level, it does not
tell us what actually causes breast cancer. The
specific hormonal aberrations that result in the pro-
liferation of susceptible stem and intermediate cells,
and the etiology of these aberrations, are not well
understood; and radiation is the only initiator that
has been identified. In the next section, our current
knowledge of the relationships of breast cancer to
specific endogenous hormones will be reviewed, and
considered in the context of the proposed model.
After that, possible initiators will be similarly con-
sidered.
Endogenous Hormones
Estrogens
Estrogens cause proliferation of human breast
tissue, so presumably would promote growth of
stem and intermediate cells. However, neither
breast cancer cases nor individuals at high risk of
breast cancer have been consistently shown to have
elevated levels of total plasma estrogens or urinary
estrogen metabolites.
There are three major endogenous estrogens in
humans: estrone (E1), estradiol (E2) and estriol (E3).
Until recently, it was thought that estriol was not
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estrogenic or carcinogenic in experimental animals
and would antagonize the effects of the other two
estrogens. Based on this premise, and observations
that the ratio EA(E, + E2) in urine (the estriol excre-
tion ratio) was low in breast cancer cases, in women
with benign breast lesions and in infertile women
with anovulatory cycles, and that it was increased
during pregnancy, Lemon (35) hypothesized that a
low urinary estriol excretion ratio (E3 ratio) facili-
tated the development of breast cancer. This hy-
pothesis was modified by Cole and MacMahon (36)
who suggested that a low E3 ratio between puberty
and about age 25 was an important determinant of a
woman's lifetime risk of breast cancer. A number of
studies were conducted to test this hypothesis by
comparing urinary E3 ratios in members of high and
low risk populations. These have previously been
reviewed (1). In the aggregate they showed, as pre-
dicted that young women from high-risk populations
have lower ratios than young women from low-risk
populations. However, estriol has since been shown
to be an active estrogen and a tumor promotor in
animal systems (37) and to occur in insufficient
levels in human plasma to counteract effectively the
effects of the other estrogens. Urinary levels of
estriol vary due to differences in the final pathways
of estrogen metabolism (38). The estriol excretion
ratio hypothesis must thus be rejected. However,
the E3 ratio must be related to some other factor
that is responsible for the international differences
in rates of breast cancer. According to the model,
this factor acts as an initiator. Therefore, either the
model is incorrect, or this factor is nonhormonal, or
hormonal aberrations may act as initiators as well
as promotors.
In Greece, (39), young parous women were also
found to have higher urinary E3 ratios than nullipar-
ous women. This observation suggests that the
same basic mechanisms that cause the international
differences in rates may also be responsible for the
protective effect of an early first child. If so, this too
suggests that the international variation in rates is
of hormonal origin.
Close relatives of women with breast cancer, who
are themselves at increased risk, do not have low
urinary E3 ratios. However, one study (40) but not
another (41) did find elevated plasma levels of El +
E2 in relatives of cases, along with elevated plasma
prolactin levels. In two studies (41, 42), higher levels
of El + E2 were found in the urine of relatives of
cases than controls. Low levels of androgens in
plasma and urine have been observed in sisters of
cases (43). These findings are difficult to interpret,
but do suggest that altered steroid hormone
production, metabolism, or excretion, perhaps
resulting in more estrogens relative to other
hormones, may play a promoting role in some
familial breast cancer. This mechanism is different
from that proposed by Knudson (33), and in-
corporated into the Moolgavkar model (31), by
which familial breast cancer was hypothesized to
result from the first event occurring in a germ cell
and causing an individual to be born with all stem
cell precursors already in the intermediate stage.
Progesterone
Progesterone is produced primarily during the lu-
teal phase of the menstrual cycle by the corpus lute-
um, and causes alveolar cell growth and differentia-
tion in the estrogen primed breast. Sherman and
Korenman (44) hypothesized that breast cancer was
caused by inadequate corpus luteum formation, and
hence estrogenic stimulation in the absence of
sufficient cyclic progesterone. This hypothesis was
subsequently modified by Korenman (45), who pos-
tulated that menarche and menopause were two
"windows" in time when anovulatory cycles are
frequent, and individuals are particularly suscep-
tible to environmental carcinogens (initiators, in
terms of the Moolgavkar model). Results of some
endocrinologic studies are not supportive of this hy-
pothesis: low risk Japanese and high risk British
women were found to have similar levels of plasma
progesterone and urinary pregnanediol (46);
daughters of women with breast cancer have been
found to have elevated levels of plasma
progesterone (40) and urinary pregnanediol (40, 42);
and members of high risk families were not found
to have unusual levels of plasma progesterone or
urinary pregnanediol (41). On the other hand, on the
Isle of Guernsey, women at increased risk of breast
cancer by virtue of an early menarche, a family
history of breast cancer or low urinary androgen
excretion, were found, on the basis of low plasma
progesterone levels, to have more anovulatory
cycles than other women (47); and infertile women
with anovulatory cycles were found to have higher
rates of breast cancer than infertile women with
normal cycles (48). If the "window" hypothesis is
valid, then only endocrinologic studies of women at
menarche or menopause would be expected to dis-
tinguish high- and low risk women, but this seems
not to explain the discrepant findings of studies of
progestogens conducted to date.
Androgens
A large prospective study conducted on the Isle
of Guernsey has shown that woman who excrete
low levels of the androgen metabolites etiocholano-
lone and androsterone have elevated risks of
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subsequent breast cancer (49). Androsterone is
androgenic whereas etiocholanolone is not, and low
risk Japanese women were found to have a higher
ratio of androsterone to etiocholanolone in their
urine, indicating that the lower risk women had
higher levels of active androgens (50). Sisters of
breast cancer cases (43) and 20- to 40-year old
women with benign breast lesions, but not older
women (51, were found to have lower levels of an-
drogens or their metabolites in their plasma and
urine than women at lower risk, although in another
study, the urinary levels of etiocholanolone did not
distinguish women with benign breast disease from
controls (52).
On balance, it seems that low levels of endoge-
nous androgens are associated with an elevated risk
of breast cancer. However, on the Isle of Guernsey,
the effects on risk of breast cancer of low urinary
etiocholanolone level, age at menarche, family
history of breast cancer, and age at birth of first
child, were independent (on a multiplicative scale)
(53). This suggests that low androgen levels are not
the mechanism by which the other three factors
considered influence the risk of breast cancer.
Prolactin
Prolactin is secreted by the pituitary gland and
acts on the estrogenprimed breast to stimulate and
maintain lactation. It is thus associated with the
functioning of differentiated cells, not the stimula-
tion of stem cell growth, and, like androgens and
progesterone, should, if anything, be related to a re-
duced risk of breast cancer. High levels of prolactin
are secreted during pregnancy, and this may be one
reason for the reduced risk of breast cancer as-
sociated with an early first birth. Most ob-
servations, however, suggest that prolactin does not
play a role in the genesis of breast cancer. Prolactin
is secreted during lactation, but breast feeding
seems not to alter one's risk of breast cancer. Nei-
ther basal plasma prolactin levels (54-58) nor levels
in response to provocative tests (57) have been
found to differ in breast cancer cases and controls,
and plasma levels in women from high- and low-risk
populations were not appreciably different (59).
Both reserpine and phenothiazines stimulate prolac-
tin production, and women who have-taken these
drugs are not at altered risk of breast cancer (1, 60,
61). One study found increased levels of prolactin in
daughters of cases (40), but two other investigations
failed to confirm this finding (41, 62).
Thyroid
Thyroid hormone probably does not play a direct
role in the genesis of breast cancer (1). Studies of
women with a variety of thyroid diseases have
shown no relationship of breast cancer risk to any
type ofthyroid condition or treatment (63-65).
In Summary
A simple hypothesis that tumor promotion in the
human breast results from either an absolute ex-
cess of active estrogens, or an excess relative to
other hormones, must be rejected for two reasons:
the results of studies of endogenous hormones do
not consistently show excess absolute or relative es-
trogen levels in individuals at increased risk of
breast cancer; and studies do not clearly and consis-
tently show an increased risk of breast cancer in
women exposed to exogenous estrogens. This is not
to imply that endogenous hormones do not act as tu-
mor promotors. They probably do, but their role is
complex and not fully understood. Evidence to date
suggests that individuals at increased risk for dif-
ferent reasons may have different hormonal aberra-
tions. For example, the aberrations related to inter-
national differences in rates appear to differ from
those that distinguish women with a family history
of breast cancer.
The possibility must also be considered that hor-
monal aberrations act as initiators. As mentioned in
the above section on estrogens, the Moolgavkar
model implies that the international variation in
rates is due to differences in the prevalence of ini-
tiators, and yet such variation has been related to
differences in endogenous estrogen (and androgen)
excretion. Alternatively, these observations on
hormone excretion may imply that the model is
incorrect.
Possible Promotors
Ionizing Radiation
Increased risk of breast cancer has been ob-
served in women who received multiple fluoro-
scopies of the chest (66-70), women treated with ra-
diation for acute postpartum mastitis (71-73), acne
(74), and benign breast diseases (73), women exposed
to atomic bombs in Japan (75, 76), and women who
worked with paint containing radium (77). The dose-
response curve appears to be linear within a wide
range of dosages (70, 72, 76, 78), but with some
evidence of a leveling off of the curve at high doses.
Rad for rad, fractionated and single exposures ap-
pear to have about the same effect on risk (78).
Breast cancer appears in excess after a latent
period of at least 8 years (67). Thereafter, the excess
risk persists for up to 30 years after exposure (70,
72). Radiation effects the risk of subsequent breast
cancer at all ages to about the same degree (78), al-
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though high doses may diminish the latent period
somewhat (72, 73).
The influence of radiation on risk varies with the
age of the women at the time of exposure. Girls ex-
posed prior to breast development are not at in-
creased risk, and those irradiated in early adulthood
are at greater risk than women irradiated later in
life (70, 73, 76-78). In addition, risk of breast cancer
was increased to a greater extent in women treated
with x-rays for postpartum mastitis following their
first child than in women so treated after the birth
of other children (79).
All of these observations are consistent with the
notion that ionizing radiation acts as an initiator in
the context of the Moolgavkar model, and that it
acts primarily on stem cells to cause the initial
event. Thus, radiation has no effect until puberty,
when stem cells start to grow and proliferate. Its ef-
fect is maximal early in adult life, when stem cells
are rapidly proliferating, and diminishes thereafter
with age as more stem cells differentiate or die.
During the first pregnancy, there is marked prolife-
ration of breast stem cells and therefore a par-
ticularly large radiation effect right after this preg-
nancy. Enhanced differentiation of stem cells then
follows the first pregnancy so the effect of radiation
after subsequent pregnancies is less. The intermedi-
ate cells thus produced by radiation, like any other
intermediate cells, are then subject to whatever
other initiating factors cause tumor cells to develop
from intermediate cells. This mechanism explains
why, after an appropriate latent period, risk is
enhanced at all subsequent ages, and why cases do
not then occur strongly clustered in time like an
infectious disease in persons following exposure to a
common source. The somewhat shortened latent
period in women who received particularly high
doses may indicate that, under such circumstances,
radiation may also act to induce second events.
The epidemiologic observations on risk of breast
cancer in relation to ionizing radiation thus support
the Moolgavkar model, and in the context of the
model, radiation serves as a prototype for tumor ini-
tiators, particularly those acting at stage one.
Unfortunately, no other initiators for human breast
cancer are known.
Familial Factors
We have seen that the familial aggregation of
breast cancer may result from an alteration of en-
dogenous hormones, and if so, that this is at vari-
ance with the Moolgavkar and Knudson models
which imply that familial breast cancer is due to the
first event occurring in a germ cell and causing the
individual to have all stem cells in the intermediate
stage. On the other hand, there are features of
familial breast cancer that are supportive of the
model, in particular the early age of onset of familial
cases and the tendency for such cases to develop bi-
lateral tumors. It is possible that both mechanisms
are operative in different familial situations.
Geographic Factors
Reasons for the marked international variation in
rates of breast cancer are unknown. They are un-
doubtedly environmental and not genetic. In the
section on endogenous hormones, it was pointed out
that the international differences in rates had been
correlated with some measures of endogenous es-
trogens and androgens, and that these observations
suggest that tumor promotors rather than initiators
may be responsible for the international differences
in rates. On the other hand, the Moolgavkar model
implies that the international differences in rates
are due to variation in exposure to initiators.
Rates of breast cancer have been correlated with
per capita consumption of various animal fats and
meats (20-22), as well as with gross national product
(20). These observations could result from the ef-
fects of either initiators or promotors, so neither
support nor refute the model.
A high fat diet could promote a breast cancer by
at least two mechanisms: it could result in obesity,
and in obese persons, there is enhanced production
of estrone from androstenedione (80); or hormone-
like substances could be produced by the action of
intestinal bacteria on bile salts, both of which may
be altered by a high fat diet (81). Alternatively, the
international difference could be due to unrecog-
nized mammary carcinogens in the environment,
the presence of which is correlated with fat or meat
consumption. These could be dietary contaminants
(82), or substances produced in the gut from the
action of intestinal bacteria on bile salts or other
substances (83). Theoretically, they could also be of
nondietary origin, although there is currently little
evidence for any such substances.
Possible Lines of Further Inquiry
The observations on androgens, estrogens, pro-
gesterone, and other hormones are not necessarily
in conflict. They may be different indicators of the
same (unknown) underlying hormonal aberration.
The production, metabolism, and excretion of these
hormones, and their resultant concentrations in
blood, urine, and breast tissue are certainly interre-
lated. These interrelationships are complex and not
fully understood, and they should be the subject of
further study.
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More information is also needed on the endocrino-
logic events associated with such risk factors for
breast cancer as a first pregnancy at an early or
late age, an early menarche and a late menopause.
Studies to clarify the mechanisms by which indi-
viduals with a family history of breast cancer are at
increased risk are needed. These should include
additional endocrinologic studies to compare various
hormones in women with single and multiple first
degree relatives with breast cancer, and in women
whose relatives have bilateral disease of early onset
and unilateral disease of later onset. Other in-
vestigations might include epidemiologic studies to
ascertain whether the recognized risk factors for
breast cancer can explain the increased risk in rela-
tives of cases. Studies of the clonal nature of familial
and nonfamilial tumors have been suggested by
Moolgavkar (31).
Additional studies to attempt to identify causes
of the international differences in rates of breast
cancer are needed. A search for determinants of a
low (or high) urinary estriol excretion ratio might
provide a clue. Much more work needs to be, and is
being, done on dietary determinants of breast can-
cer risk. In addition to initiators and promotors,
dietary factors that might act to prevent breast can-
cer should be considered.
It is well known that estrogens increase the
amount of calcium in bone. Their influence, and that
of other hormones, on the calcification of extraosse-
ous tissues is unknown, and should be studied. Two
possible lines of inquiry follow.
The first derives from the observation that wom-
en with benign breast lesions characterized by duct-
al cell hyperplasia with calcium deposits have been
shown to be at a particularly high risk of breast can-
cer (29). Perhaps the presence of calcium in these le-
sions is an indicator of some endogenous hormonal
aberration that is also responsible for the develop-
ment of breast cancer. Hormonal determinants of
these mammary calcifications should, therefore, be
investigated.
The second suggested line of inquiry derives
from a theory for the genesis of breast cancer pro-
posed by Cohen et al. (84) in 1978 that has since
received little attention. They suggested that calcifi-
cation of the pineal gland results in decreased pro-
duction of melatonin, which normally inhibits pitui-
tary gonadotropin and ovarian estrogen production,
and that this results in an increase in estrogen
levels, which leads to breast cancer. In support of
this hypothesis, they cited evidence that the preva-
lence of calcified pineal glands is correlated with the
incidence of breast cancer in various geographical
areas. The cause of pineal calcification is unknown.
Perhaps this calcification, too, is influenced by estro-
gens or other steroid hormones. If it is, breast can-
cer might result from the development of an abnor-
mal positive feedback system in which calcification
of the pineal causes a decrease in melatonin, which
causes an increase in pituitary gonadotropins, which
causes an increase in estrogens (absolute or relative
to other steroid hormones), which further increases
calcification of the pineal, etc. This mechanism is
conjectural, but plausible, and implies that studies
of possible hormonal (and other) determinants of
pineal calcification would be of value.
Summary and Conclusions
The etiology of breast cancer is complex, multi-
factorial and poorly understood. The epidemiologic
features of the disease are compatible with a two-
stage carcinogenic process, with promotors acting
to enhance the growth of stem and intermediate
cells, and initiators acting to cause stem and inter-
mediate cells to give rise, respectively, to inter-
mediate and tumor cells. Endogenous hormones
most probably act as promoters but the specific in-
ternal hormonal milieu responsible is unknown. It is
not an absolute excess of estrogens, and probably
not a simple excess relative to other steroid hor-
mones such as androgens, progestogens, or inactive
estrogens. Different aberrations may be operative
in different circumstances.
Ionizing radiation probably acts as an initiator,
primarily on stem cells. Other initiators undoubt-
edly exist, but have not been identified. The Mool-
gavkar model implies that international differences
in risk of breast cancer, and familial aggregation of
cases, are due to initiators acting on breast stem
cells and germ cells, respectively. However, results
of endocrinologic studies suggest that hormonal
aberrations might be involved. If so, then either the
inferences drawn from the model are incorrect and
the familial aggregation of cases and the variation
in risk among countries are mediated by promotors,
rather than initiators, or hormonal aberrations are
highly correlated with the presence of initiators, or
hormones can act as initiators. Several possible
lines of further investigation into the etiology of
breast cancer, some to clarify the role of endogne-
ous hormones, have been suggested in this review.
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